We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 903% below its sector, cheaper than its peers on earnings.
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save ONESOURCE.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.